Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer

International Journal of Radiation Oncology Biology Physics

Volumn 52, Issue 2, 2002, Pages 397-405

  Formenti, Silvia C ^a   Spicer, Darcy ^b   Skinner, Kristin ^b   Cohen, Deidre ^b   Groshen, Susan ^b   Bettini, Anna ^b   Naritoku, Wesley ^b   Press, Michael ^b   Salonga, Dennis ^b   Tsao Wei, Denice ^b   Danenberg, Kathy ^b   Danenberg, Peter ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

HER2 neu; Locally advanced breast cancer; p53; Paclitaxel; Pathological response (pPR and pCR)

Indexed keywords

GENES; PATHOLOGY; PROTEINS; RADIATION; TUMORS;

LOCALLY ADVANCED BRAEST CANCER (LABC);

ONCOLOGY;

BETA TUBULIN; CIMETIDINE; CYCLOOXYGENASE 2; DEXAMETHASONE; ESTROGEN RECEPTOR; METABLASTIN; MICROTUBULE ASSOCIATED PROTEIN 4; MOLECULAR MARKER; ONCOPROTEIN; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; POLYMERASE CHAIN REACTION; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION FIELD; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; GENE EXPRESSION; GENES, ERBB-2; HUMANS; MIDDLE AGED; PACLITAXEL; RADIATION-SENSITIZING AGENTS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036472185     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)02655-4     Document Type: Article

References (64)

1. Neo-adjuvant chemotherapy in the combined modality approach of locally advanced non-metastatic breast cancer
2. Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy
3. Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard poly-chemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide; Prognostic and therapeutic implications
4. Breast conservation and prolonged chemotherapy for locally advanced breast cancer; The University of Michigan experience
5. High dose multimodality therapy with autologous stem-cell support in stage IIIB breast carcinoma
6. Detection of tumor cells in bone marrow of patients with primary breast cancer; A prognostic factor for distant metastasis
7. The effect of systemic therapy on local-regional control in locally advanced breast cancer
8. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy
9. Concurrent paclitaxel and radiation therapy for breast cancer
10. Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer
11. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy
12. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation
13. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer; Phase III randomized Intergroup study 0099
14. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
15. Post-operative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and GE junction; Results of Intergroup Study INT-0116 (SWOG 9008)
16. Locally advanced breast cancer; A model for translational research
17. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
18. Problems in evaluating response of primary breast cancer to systemic therapy
19. Primary chemotherapy in operable breast cancer; Eight-year experience at the Milan Cancer Institute
20. Clinical course of breast cancer patients with complete pathological primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
21. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis
22. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway
23. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients
24. Paclitaxel-induced radiosensitization; Myth or reality?
25. Taxol; Mechanisms of action and resistance
26. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes
27. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes
28. Overexpression of full- or partial-length MAP4 stabilizes microtubules and alters cell growth
29. Genetic susceptibility to microtubule-active cancer chemotherapeutic drugs; p53 action and the role of microtubule associated protein 4 (MAP4)
30. Wild-type p53 negatively regulates the expression of a microtubule-associated protein
31. Regulation of microtubule dynamics by extracellular signals; cAMP-dependent protein kinase switches off the activity of oncoprotein 18 in intact cells
32. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
33. Molecular effects of paclitaxel; Myths and reality (a critical review)
34. Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage
35. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs
36. p21 is associated with cyclin D1, p16INK4a and pRb expression in resectable non-small cell lung cancer
37. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells
38. The HER-2/neu oncogene in breast cancer; Prognostic factor, predictive factor, and target for therapy
39. Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogen
40. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells
41. Preoperative paclitaxel and radiotherapy for locally advanced breast cancer; Surgical aspects
42. Acute radiation morbidity score criteria (RTOG)
43. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
44. Real time quantitative PCR
45. A novel method for real time quantitative RT-PCR
46. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms
47. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer
48. Paclitaxel alone and in combination with radiation therapy as neo-adjuvant approach to locally advanced breast cancer (LABC); Clinical and pathological response
49. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer
50. High incidence of pathological complete remission following sequential primary chemotherapy (PC) in unfavorable locally advanced breast cancer (LABC)
51. Clinical course of locally advanced breast cancer (LABC) patients with pathological response to concurrent 5-Fluorouracil and radiation (FU/RT)
52. Apoptosis in the pathogenesis and treatment of disease
53. p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32B
54. Elevated expression of bcl-2 and bcl-x by intestinal intraepithelial lymphocytes; Resistance to apoptosis by glucocorticoids and irradiation
55. Dual mechanisms of submicromolar taxol on human leukemia HL-60 cells
56. Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death
57. Enhanced radioresponse of paclitaxel-sensitive and -resistant tumors in vivo
58. Cell cycle control and cancer
59. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
60. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression
61. Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells